OBJECTIVES: Prior to the approval of the first disease modifying therapy (DMT) in the mid 1990’s there were limited options for treatment for Multiple Sclerosis (MS). DMTs have transformed MS by delaying its progression and reducing relapses. However, these therapies can be expensive and may have side effects. This study aimed to: 1) Characterize the preference of neurologists and the general public between the pre-DMT time period (pre-1995) andcurrent landscape, and; 2) Assess the public’s willingness to pay (WTP) for insurance to cover DMTs . METHODS: We conducted a national online survey. Part 1 asked neurologists and respondents from the general population to choose between pre-DMTs and current DMT regimens. In Part 2, general population respondents participated in a bidding game to determine WTP for health insurance to cover DMT costs should they develop MS. RESULTS: Most respondents (76% of neurologists and 65% of the general population)preferred DMTs over pre-DMT era treatments. On average, the general population had a WTP of $22per family member per month (PMPM) ($16 median) for MS DMT insurance. Respondents who chose pre-DMT era treatments had a numerically lower WTP($19 mean,$14 median PMPM), compared with those who preferred DMTs ($23 mean, $17 median PMPM). CONCLUSIONS:  Although most respondents prefer DMTs to non-DMTs, some general population respondents and neurologists prefer pre-DMT therapies. The neurologist result is surprising given the strong physician group recommendations for use of DMTs at the earliest point possible. Ex-ante WTP for MS DMT insurance coverage is 4-5 times the current PMPM cost of MS DMTs, which was $4.43 in 2015.